{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:17:04Z","timestamp":1789755424362,"version":"4.0.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) has cardiometabolic risk factors, such as obesity and type 2 diabetes, and has been reported to have a potentially higher risk of mortality than conventional steatotic liver diseases. Liver fibrosis develops and can progress to cirrhosis and hepatocellular carcinoma. Although some antidiabetic agents have been reported to ameliorate the condition, no specific medical treatment has been developed to date. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) that has shown efficacy against MASH in some clinical trials. However, these trials were limited to those with mild-to-moderate fibrosis and their history of treatment was often unclear. Here, we report the case of a 50-year-old man with a 16-year history of diabetes. He demonstrated poor control of his diabetes with elevated liver enzymes. A liver biopsy was performed and he was diagnosed with steatohepatitis. Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023. The histological examination found cirrhosis and liraglutide was switched to tirzepatide. Over 6 months of administration of tirzepatide, the patient\u2019s glycated hemoglobin and elevated liver enzyme levels improved. A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis. A diagnosis of steatotic liver disease was made. Although some previous studies had demonstrated an amelioration of liver fibrosis and an improvement in the prognosis of patients following GLP-1RA treatment, effective medications for patients with severe fibrosis or who are refractory to treatment with GLP-1RAs has not been identified to date. We reported a case with severe MASH whose condition had ameliorated by switching from conventional GLP-1RAs to tirzepatide.<\/jats:p>","DOI":"10.3389\/fendo.2025.1501984","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:37Z","timestamp":1748232637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuki","family":"Oe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Aimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Kitakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0109","article-title":"Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis","volume":"30","author":"Crane","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i11.1307","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice","volume":"25","author":"Zhou","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e01544","DOI":"10.14309\/crj.0000000000001544","article-title":"Dramatic changes in thiopurine metabolite levels in a patient with inflammatory bowel disease treated with tirzepatide for weight loss","volume":"11","author":"Klein","year":"2024","journal-title":"ACG Case Rep J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001484","article-title":"A rare case of tirzepatide-induced hepatotoxicity","volume":"11","author":"Sohal","year":"2024","journal-title":"ACG Case Rep J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"004813","DOI":"10.12890\/2024_004813","article-title":"Tirzepatide-related acute liver injury","volume":"11","author":"Abdullah","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15566","article-title":"Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes","volume":"26","author":"Cariou","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0872","article-title":"Achieving normoglycemia with tirzepatide: analysis of SURPASS 1\u20134 trials","volume":"46","author":"Rosenstock","year":"2023","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-024-01472-w","article-title":"Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study","volume":"23","author":"Sawamura","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15680","article-title":"Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population","volume":"26","author":"Buckley","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic fatty liver disease and obesity treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr Obes Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/dom.14843","article-title":"Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents","volume":"25","author":"Geisler","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0873-y","article-title":"Adipose tissue as a buffer for daily lipid flux","volume":"45","author":"Frayn","year":"2002","journal-title":"Diabetologia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0093-z","article-title":"Adipogenesis and metabolic health","volume":"20","author":"Ghaben","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401149","article-title":"Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation","volume":"193","author":"Varol","year":"2014","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cells9020461","article-title":"Cellular interplay as a consequence of inflammatory signals leading to liver fibrosis development","volume":"9","author":"Ignat","year":"2020","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03586-1","article-title":"The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review","volume":"80","author":"Zachou","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.v34.11","article-title":"Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9324","DOI":"10.3390\/ijms24119324","article-title":"Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1501984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:40Z","timestamp":1748232640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1501984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":37,"alternative-id":["10.3389\/fendo.2025.1501984"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1501984","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1501984"}}